4/A//SEC Filing
AzurRx BioPharma, Inc. 4/A
Accession 0001415889-17-001128
$GRDXCIK 0001604191operating
Filed
Jul 4, 8:00 PM ET
Accepted
Jul 5, 8:24 PM ET
Size
7.9 KB
Accession
0001415889-17-001128
Insider Transaction Report
Form 4/AAmended
BALK MATTHEW
10% Owner
Transactions
- Sale
Common Stock
2017-06-30$3.00/sh−100,000$300,000→ 1,687,796 total - Sale
Common Stock
2017-06-30$3.50/sh−60,000$210,000→ 1,627,796 total
Pelican Partners LLC
10% Owner
Transactions
- Sale
Common Stock
2017-06-30$3.00/sh−100,000$300,000→ 1,687,796 total - Sale
Common Stock
2017-06-30$3.50/sh−60,000$210,000→ 1,627,796 total
Footnotes (1)
- [F1]Securities were sold in private, negotiated transactions. The purchasers agreed to not sell the securities purchased for a period of 120 days, resulting in a lock-up during such period.
Documents
Issuer
AzurRx BioPharma, Inc.
CIK 0001604191
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001604191
Filing Metadata
- Form type
- 4/A
- Filed
- Jul 4, 8:00 PM ET
- Accepted
- Jul 5, 8:24 PM ET
- Size
- 7.9 KB